Monrovia, United States
Rampart Bioscience, founded in 2019, is pioneering advancements in the Biopharma and Biotechnology industries. Based in the United States, the company aims to lead a new era of effective, safe, and accessible gene medicines, targeting patients with genetically driven diseases. Its innovative approach integrates capabilities from gene delivery, protein sciences, and clinical translation to surpass the current limitations of gene therapies.
The key differentiator for Rampart Bioscience lies in its novel non-viral DNA delivery system, which aspires to achieve higher standards of potency, durability, redosability, and safety. Such innovations are set to reshape the treatment landscape and present new opportunities for addressing unmet medical needs.
In the most recent funding round—an $85.00M Series A investment in October 2023—the company garnered the support of prominent investors like RA Capital Management, HealthCap, OrbiMed, and Forbion Capital Partners, underscoring strong market confidence in its potential.
